Compare AEO & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AEO | ARQT |
|---|---|---|
| Founded | 1977 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 3.2B |
| IPO Year | 2004 | 2020 |
| Metric | AEO | ARQT |
|---|---|---|
| Price | $17.90 | $25.46 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 14 | 7 |
| Target Price | $18.55 | ★ $37.00 |
| AVG Volume (30 Days) | ★ 6.2M | 2.4M |
| Earning Date | 09-09-2026 | 10-27-2026 |
| Dividend Yield | ★ 2.81% | N/A |
| EPS Growth | N/A | ★ 88.79 |
| EPS | ★ 0.92 | 0.03 |
| Revenue | ★ $5,547,236,000.00 | $376,072,000.00 |
| Revenue This Year | $5.54 | $42.88 |
| Revenue Next Year | $3.42 | $27.84 |
| P/E Ratio | ★ $19.88 | $899.67 |
| Revenue Growth | 4.10 | ★ 91.34 |
| 52 Week Low | $14.06 | $19.30 |
| 52 Week High | $28.46 | $31.77 |
| Indicator | AEO | ARQT |
|---|---|---|
| Relative Strength Index (RSI) | 62.04 | 53.37 |
| Support Level | $16.87 | $24.91 |
| Resistance Level | $18.50 | $28.20 |
| Average True Range (ATR) | 0.62 | 1.44 |
| MACD | 0.33 | 0.16 |
| Stochastic Oscillator | 85.52 | 62.81 |
American Eagle Outfitters Inc is a specialty retailer. The company is engaged in the retail of apparel and accessories with company stores in the United States, Canada, Mexico, and Hong Kong. The Company leases all store premises, regional distribution facilities, some of its office space, and certain information technology and office equipment. American Eagle also has its online business. It operates in two segments: American Eagle and Aerie. The majority of its revenue comes from its primary brand, American Eagle, which offers an assortment of specialty apparel, accessories, and personal care products for women and men. Geographically, it generates the majority of its revenue from the United States.
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.